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INTRODUCTION
Auditory neuropathy (AN) is a condition caused by a deficiency of synchronous neural activity of the cochlear nerve and is related 
to injuries that can affect the inner hair cell synapse, spiral ganglion, axon, the myelin sheath, and nerve dendrite [1-3].
The term has been used to describe a singular situation that affects both adults and children with diagnostic criteria that charac-
terizes the normal functioning of outer hair cells, by examination of these otoacoustic emissions and the abnormal or absent op-
eration of the cochlear nerve, through the presence of cochlear microphonic (CM) or by the absence or dyssynchrony of the waves 
generated in the auditory-evoked potential/brain response (ABR). Generally, patients still have difficulty in speech discrimination, 
inconsistent with the pure tone audiogram findings [1, 2].
The term AN was first used in 1996 and later changed to the AN spectrum disorder during the Conference of Consensus on Auditory 
Neuropathy/dyssynchrony in Como, Italy, in 2008 because of the different clinical forms of this peculiar disease [2, 4-6].
The pathophysiology of this condition remains unclear, although in recent years, the identification of genes involved in the patho-
genesis of AN, both presynaptic and post-synaptic, has significantly contributed to the diagnosis and better understanding of the 
mechanisms involved in this clinical disorder [1, 6, 7].
In the past, AN patients were treated in different ways, depending on their degree of hearing loss. Thus, treatment ranged from a 
simple observance to the use of hearing aids and frequency modulation (FM) system with predominantly unsatisfying results, such 
as poor speech or hearing rehabilitation [8, 9].
As the conventional treatment of AN has proved, in most cases, refractory to conventional amplification, the cochlear implant (CI) 
approach is an alternative therapy for this condition [1, 3, 5].
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Performance of Cochlear Implants in Pediatric Patients 
with Auditory Neuropathy Spectrum Disorder
OBJECTIVE: To describe the performance and results of CIs (cochlear implant) in patients with AN (auditory neuropathy) and to present a medical 
literature review. 
MATERIALS and METHODS: Retrospective chart review of patients with AN who were treated with CI. The mesh terms used for the review in the 
Pubmed and Scopus databases were as follows: “hearing loss, cochlear implants, rehabilitation of persons with hearing impairment, auditory 
neuropathy”. Statistical Analyses: The Mann-Whitney test was performed. 
RESULTS: The sample consisted of 10 patients. The mean age at surgery was 4.3 years, range 2-16 years. The average length of CI use was 5.2 years. 
The comparison of hearing levels before and after CI use showed a significant improvement in all patients, with p<0.05. All of them also reported 
an increase in overall satisfaction 1 year after the procedure. A CI is the standard treatment for the hearing rehabilitation of patients with severe 
profound hearing loss who do not benefit from conventional hearing aids. There are diseases such as AN that also invoke a discussion in the 
literature regarding CI benefits. 
CONCLUSION: Individuals with an demonstrated a significant gain in hearing levels and language use with CI. 
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implants
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Cochlear implants (CI) currently has ample evidence for its efficacy in 
the treatment of various forms of deafness, from unilateral to bilater-
al cases with severe to profound hearing loss. It also has been shown 
as an alternative for hearing rehabilitation in many conditions, such 
as in deafness with residual hearing at low frequencies and AN. In 
AN cases, CI is an option when the patient has not had a good re-
sponse to conventional hearing aids and an adequate development 
of speech [1, 3, 5, 10, 11].
Although it has been demonstrated that the earlier use of CI in chil-
dren with AN with severe or profound hearing loss leads to an im-
portant benefit in most cases, the situation is still challenging in cases 
when the hearing loss is moderate [1, 3]. Thus, CI has shown conflicting 
results worldwide, probably because AN must be heterogeneous and 
have different etiologies [5].
A recent systematic review evaluated the improvement of speech 
development in children with AN treated with CIs and showed fa-
vorable results after CI regarding hearing and speech parameters but 
concluded that the evidence for CI is still weak and further studies 
are needed to clarify where and when CI could be applied as a good 
option for pediatric patients with AN [12].
Regarding the etiologic heterogeneity of AN, it is not surprising that 
the auditory performance of CI treatment in AN patients is also vari-
able. Therefore, the use of CIs for individuals with AN has been rela-
tively controversial in the literature [13, 14].
The identification of specific mutations involved with AN has impli-
cations not only for diagnosis but also for rehabilitation because a 
good outcome is expected with CI use when the disturbance is due 
to presynaptic mutations (OTOF gene) or postsynaptic mutations in 
the distal portions of the auditory fibers (DIAPH3 gene). However, it 
is expected that CIs will have limited benefit for all forms of AN in-
volving the auditory nerve [14, 15]. Therefore, the genetic and molecu-
lar diagnosis of AN is also important in the choice of an appropriate 
treatment and follow-up of those subjects.
Cochlear implants (CI) is becoming a choice of treatment for patients 
with AN. This kink of the hearing disorder with mild-to-moderate 
hearing loss remains a challenge in terms of the treatment options, 
even to experts in this area.
Thus, this paper aims to study and demonstrate the performance 
and developing speech skills of pediatric patients with AN spectrum 
disorder treated with CI and to evaluate this device as a treatment 
option.
MATERIAL and METHODS
A cross-sectional and case series study was conducted, through a 
retrospective analysis of the records of patients diagnosed with bilat-
eral hearing loss, suspected of AN spectrum disorder (NA), followed 
in the hearing center at a tertiary university hospital and undergoing 
CI surgery.
The parameters studied were age, sex, onset of hearing loss (congen-
ital, childhood, adolescence, or adult), gestational/perinatal/genetic 
background, and the results of electrophysiological hearing tests, 
namely ABR, otoacoustic emissions by distortion product (OAE), and 
a search for CM.
Perinatal and gestational histories were any situations described in 
the past of the patients, such as prematurity, jaundice, kernicterus, 
neonatal intensive unit hospitalization, meningitis, severe neonatal 
infections (such as sepsis and pneumonia), genetic syndromes, con-
comitant neurological diseases, infectious diseases (such as rubella 
and toxoplasmosis), clinical systemic comorbidities (such as hyper-
tension and diabetes mellitus), and a family history of deafness.
The age group was defined as the beginning of the onset of symp-
toms, as follows: congenital (up to 1 year old), childhood (between 1 
and 10 years old), adolescents (between 11 and 18 years of age), or 
adult (over 18 years life). Adults were excluded from this paper.
The clinical diagnosis of AN was established as follows: ABR with 
missing or abnormal responses and the presence of OAE and/or of 
CM with no anatomical alteration of the VIII cranial nerve. All patients 
had no acoustic reflex, and the presence of the cochlear nerve was 
assessed by nuclear magnetic resonance (MRI) and computed to-
mography (CT).
Molecular Study
Genomic DNA was extracted from patients’ peripheral venous blood 
according to standard protocols. GJB2 mutations were screened by a 
direct sequencing of the gene coding region [16, 17] and the exon 1 and 
flanking splice donor site [18].
Genomic DNA was extracted from patients’ peripheral blood, accord-
ing to standard protocols. All samples were tested for mutations in 
the GJB2 gene as well as for the deletions del(GJB6-D13S1830) and 
del(GJB6-D13S1854) in the GJB6 gene, the mitochondrial mutation 
m.A1555A>G in the MTRNR1 gene, and the p.Q829X mutation in the 
OTOF gene. Mutations in the GJB2 gene were screened by direct se-
quencing of the coding region of the gene [19, 20]. 
Multiplex-PCR methodology was used to detect the del (GJB6-
D13S1830) and del(GJB6-D13S1854) mutations in the GJB6 gene [21, 22]. 
The investigation of the mutations m.1555A>G and p.Q829X was per-
formed using PCR, followed by digestion with BsmAI (New England 
BioLabs, Inc.; Ipswich, MA, USA) and BfaI (New England BioLabs, Inc.) 
restriction endonucleases, respectively [23, 24].
Inclusion and Exclusion Criteria
Inclusion criteria were patients with AN submitted to CIs with bilater-
al sensorineural hearing loss, normal otoscopy, an absence of middle 
ear disease, and no acoustic reflex.
Clinical spectrum of AN was considered when audiological tests were 
compatible with the following:
A) OAE present and ABR absent, or
B) OAE absent and ABR absent and CMs present, or
C) imaging (MRI/CT) showing the presence of VIII cranial nerve 
and excluding retrocochlear alterations.
All patients who did not fulfill these criteria were excluded from the 
study.
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Sample: Patients with a clinical diagnosis of AN accompanied in the 
auditory hearing health care service of a tertiary care university hos-
pital in the last 3 years submitted to CIs.
Only patients who had undergone audiological and electrophysio-
logical testing with our team of speech experts with the same equip-
ment were included in the sample.
Adults were excluded from this study and only pediatric patients 
were studied.
Audiological Evaluation
Audiological tests were performed including impedanciometry, 
speech, and pure tone audiometry. The tests were performed using 
an audiometer AC30-SD25 (Interacoustics; Copenhagen, Denmark), 
calibrated according to ISO 389 standards/64.
The Otoacustic Emissions (OAE) distortion products were performed 
at frequencies of 700-8,000 Hz with a stimulus at 65-55 dB SPL, with a 
frequency ratio of 1.22. OEA was considered present when the signal/
noise ratio was greater than 6 dB, and with a reproducibility ≥70%.
The tests from ABR and CM were performed with insert earphones. 
A stimulus of 100 dB HL was used for ABR covered with frequencies 
between 250 and 8.000 Hz, with a duration of 100 microseconds, and 
condensed and rarefied polarities. The abnormality of ABR was de-
fined as the absence of wave formation or severe changes in mor-
phology of the same with up to a 100 dB HL stimulus.
Cochlear Microphonism (CM) was evaluated in tests from ABR, with 
the feature of inverting the polarity (condensed and rarefied). When 
CM was positive with a stimulus of 100 dB, the HL electrophysiologi-
cal threshold, in decreasing order, was researched.
For ABR, which was repeated at least twice, the AT-235 device (Inter-
acoustics; Copenhagen, Denmark), was used.
Hearing loss impairment was classified through audiometry stratifica-
tion into mild, moderate, severe/severe, or profound hearing loss [25].
Speech perception tests: During preoperative evaluation, all subjects 
underwent a speech perception test on the same day of their sur-
gery. The speech perception test was based on several studies in the 
English language, adapted and developed for Portuguese language 
by Bevilacqua et al. [26]. Patients performed the tests with hearing 
aids, in a quiet and peaceful place (best aided condition).
Postoperatively, all subjects repeated the speech perception test with at 
least 1 year experience with the CI. The tests were performed using CI. 
The same audiologist performed all the tests (pre- and postoperative).
Three protocols to evaluate the patients’ performance language and 
hearing were used because most of them were children and pre-lin-
gual developed. The scales used were as follows: IT MAIS (Meaningful 
Auditory Integration Scale for Young Children), MUSS (questionnaire 
for assessing oral language), and GASP (The Glendonald Auditory 
Screening Procedure, review of speech perception in profound deaf 
children from five years old) [27-29].
Such scales are widely used in this age group of patients and were 
adapted to the Portuguese language. IT MAIS and MUSS are proto-
cols that are answered by the parents, but these scores are deter-
mined by the inquiring professional based on the examples that 
parents give for each question. It is a way of assessing patients in the 
first year of implant because they are still in the receptive language 
stage and have no spoken language, highlighting that IT MAIS has a 
greater focus on hearing, whereas the MUSS score has a greater focus 
on language acquisition [27-29]. The GASP has been used in patients 
aged more than 5 years.
Subjective evaluations: When patients did their postoperative speech 
tests, they were asked to rate the quality of their experience with CI 
compared to last year on a Likert scale ranging from 0 to 10, similar to 
the visual analog scale. A score of 0 indicates that the user regretted 
the intervention and would not recommend it to others and felt that 
they were better off before with just their hearing aids. A score of 10 
indicates that the user was completely satisfied with the work and 
highly recommended it.
Statistical Analysis
The data were analyzed using descriptive analysis, with the mean, 
median, and standard deviation tabs. The software SIGMA XL was 
used to perform all statistical analysis (SigmaXL Inc.; Kitchener, On-
tario, Canada).
The Chi-square and the Mann-Whitney test were used to compare 
the groups of samples as they are nonparametric tests applied for 
two independent samples.
The confidence interval was of 95%, and a p value of <0.05 was con-
sidered statistically significant.
Ethical Considerations
This study was previously approved by the Research Ethics Commit-
tee of the Faculty of Medical Sciences of the University of Campinas 
(Report number 396/2006).
RESULTS
A total of 19 patients were selected, but only 10 patients completed 
the full inclusion criteria presented above. Table 1 summarizes the 
main clinical demographics findings of these patients.
This table (Table 1) highlights that all the selected cases were pedi-
atric, pre-lingual, and not oralized. In 50% of the cases, it was found 
that there were a presence of otoacoustic emissions with absence/
abnormalities at ABR, and in the rest of the patients, AN was suspect-
ed and supported by the presence of CM.
Figure 1 shows the performance of patients according to the lan-
guage, speech, and hearing evaluation through the application of 
the scales IT MAIS, MUSS, and GASP. In patients over the age of five (5) 
years, the GASP was used to assess the language, and in the younger 
ones, the MUSS was selected to evaluate this topic. IT MAIS had a 
focus on the largest review of the hearing improvement.
In The Glendonald Auditory Screening Procedure (GASP) analysis 
(p=0.002), there was a statistically significant improvement with the 
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use of CI. There was better performance trend with the CI on the 
assessment by IT MAIS (p=0.054). Regarding the MUSS, no relevant 
statistical significance (p=0.35) was obtained in this topic evaluation.
Table 2 demonstrates the audiometric data of patients preopera-
tively, with the use of hearing aids (individual sound amplification 
devices), and after surgery with the use of CIs. Statistical evaluation 
compared the preoperative time (with the use of hearing aids) with 
the postoperative time (with the use of CI). There was a statistically 
significance at all frequencies analyzed, with p<0.05.
The patients were divided into two groups, regarding the age when 
they were submitted to CI surgery. Group 1 was implanted before 
4-years old and Group 2 patients were implanted at more than 
4-years old. Each group comprised five patients and we did not find 
any difference between the groups (p>0.05) in all the analyses, ex-
cept that the Group 1 patients had more time using the CIs, which is 
normal because they were submitted to the surgery earlier than the 
other patients.
We also tried to perform two groups regarding the residual hearing. 
One group involved patients that had residual hearing (low/mod-
erate hearing loss), while the other group had no residual hearing 
(severe/profound hearing loss), and we did not find any difference 
between the groups (p>0.05) in all the analyses.
DISCUSSION
The Auditory Neuropathy (AN) is a form of sensorineural hearing loss 
recently described and it is estimated that its prevalence is about 10-
15% of newborns with sensorineural hearing loss [30].
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Age at surgery time 4 years and 4 months variation: 2 years and 6 months to 6 years and 1 month
 Average: 4.31 years
 Median: 4.15 years
 Standard deviation: 1.4726 years
CI - duration of use 5 years and 3 months variation: 1 year and 1 month to 13 years and 6 months
 Average: 5.24 years
 Median: 2.92 years
 Standard deviation: 4.5319 years
Gender 7 M: 3 F
OAE 50% presents
CM 50% presents
ABR 100% absent or abnormal
Genetics findings 30% - mutations - homozygous at GJB2 gene (c.35delG/c.35delG) 70% - no mutations (normal)
Onset of symptoms 100% at congenital age
Anatomical changes (CT and MRI) Normal - No abnormalities at 100% of the cases
Etiologic factors Prematurity - 60% (mean 33 weeks)
 NICU - 60% (average 25 days)
 Family background - 10% brother with HNS
 Neonatal jaundice - 10%
 Cardiopulmonary stop- 10% (neonatal)
 Meningitis - 0 cases
Postoperative satisfaction (VAS - visual analog scale) Average: 7.7 points
 Median: 8 points
 Standard deviation: 1.1595 points
Total 10 patients
CI: cochlear implant; OEA: otoacoustic emission (distortion product); ABR: auditory brain stem response; CT: computed tomography; RNM: nuclear magnetic resonance
Table 1. Demographic clinical data of the patients
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Figure 1. Performance of patients on the scales of IT MAIS, MUSS, and GASP
The degree of hearing loss found in patients with AN varies from 
moderate to severe and the treatment of these patients is a special 
challenge for physicians and speech therapists, since the audio-
metric thresholds tend to fluctuate, as well as the measurements 
of speech performance. Those described situations and parame-
ters above in many times do not correspond to the degree of hear-
ing loss [30].
Classic and accepted CI criteria do not include AN as one of their 
treatment options, especially in cases where there is AN with pure 
tone thresholds consistent with mild to moderate hearing loss, which 
could be considered as a nonsense indication.
Recently, several groups of specialists in hearing surgical rehabilita-
tion began to indicate CI to their patients with NA. Those patients 
were submitted to CI when they did not show improvements with 
the standard “medical treatment” (speech therapy and/or hearing 
aids). This resulted in a change of concepts and paradigms and gen-
erated further discussion among professionals involved and about 
the interfaces with the AN patients.
The discussions and arguments are very complex, since most pa-
tients are pediatric and naturally not oralized. This is a great difficulty 
because it does not allow simple and objective assessments of the 
indication of CIs used in oralized deaf patients (post-lingual), such as 
the speech perception test.
Subject Time 250 500 1 2 3 4 6 8 SRT SRI
1 Pre-op 70 90 120 120 120 120 120 120 100 dB 68%
 Pre-op with HA 50 70 90 120 120 120 120 120 90 dB NA
 Post-op with CI 20 30 25 25 25 25 20 NA 65 dB 92%
2 Pre-op 120 50 65 65 120 70 120 120 NA NA
 Pre-op with HA 120 40 45 50 120 55 120 120 80 dB 92%
 Post-op with CI 25 25 25 20 25 25 20 25 55 dB 94%
3 Pre-op 45 50 85 100 120 120 120 120 NA NA
 Pre-op with HA 30 35 45 45 70 90 120 120 NA NA
 Post-op with CI 25 25 20 20 30 30 25 60 70 dB 68%
4 Pre-op 120 80 85 90 75 75 120 120 NA NA
 Pre-op with HA 120 55 55 60 65 65 120 120 NA NA
 Post-op with CI 25 30 35 35 30 35 45 75 70 dB 74%
5 Pre-op 120 70 70 80 70 60 120 120 NA NA
 Pre-op with HA 120 60 50 55 55 55 120 120 90 dB NA
 Post-op with CI 20 25 20 20 20 25 15 35 60 dB 80%
6 Pre-op 120 110 110 120 120 120 120 120 NA NA
 Pre-op with HA 120 60 55 80 120 85 120 120 NA NA
 Post-op with CI 45 35 35 30 30 30 25 35 85 dB 68%
7 Pre-op 120 120 120 120 120 120 120 120 NA NA
 Pre-op with HA 120 120 120 120 120 120 120 120 NA NA
 Post-op with CI 20 25 40 30 35 40 60 65 NA 42%
8 Pre-op 75 95 120 120 120 120 120 120 NA NA
 Pre-op with HA 120 60 55 85 95 120 120 120 80 dB NA
 Post-op with CI 35 35 30 40 35 50 55 NA 60 dB 84%
9 Pre-op 55 100 120 120 120 120 NA NA NA NA
 Pre-op with HA 20 40 50 60 70 75 NA NA NA NA
 Post-op with CI 25 30 30 30 30 35 40 45 NA NA
10 Pre-op 75 95 115 110 120 120 120 120 95 dB 70%
 Pre-op with HA 75 95 115 110 120 120 120 120 85 dB 70%
 Post-op with CI 55 50 45 50 50 40 50 85 70 dB 82%
HZ: frequencies in Hertz; SRT: speech recognition threshold; SRI: speech recognition index; NA: not applicable/unrealized; HA: hearing aids; CI: cochlear implant
Table 2. Audiometric findings of the patients
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This test (speech perception) has a fundamental importance for indi-
cating and monitoring patients that are to be submitted to CIs, but it 
has extremely limited use in not oralized patients.
So, for not oralized patients, subjective rating scales are used that 
focus on language and hearing gains. Such scales are for the most 
part subjective and often the application depends on the support 
and active participation of parents/carriers, since these patients are 
children and are not oralized.
Several reports indicate that child users of CI show great variabili-
ty in relation to its results. A possible cause for this variation is the 
impact of cognitive impairment or the present development within 
one-third of the patients with AN and this can affect the performance 
results with CI [31].
In Budenz et al. study [31], children with the diagnosis of AN without 
these confounding factors and who had received CI presented lan-
guage development comparable to that of other children with sen-
sorineural hearing loss also treated with CI.
Another recent paper highlighted 17 children who had just AN, while 
another nine had some cognitive or associated development deficits. 
The two groups were compared with patients treated with CI due to 
sensorineural hearing loss of cochlear origin, and it was shown that 
children with AN without other factors and the cochlear loss group 
showed similar results regarding hearing with CI surgery, while nine 
patients with associated disease showed some benefit with CI, but 
this was dependent on non-aural ways of communication (signal/
gesture language) [31, 32].
In an Asian analysis, two patients with AN, with post-lingual/oralized 
hearing loss (one moderate and one severe), underwent unilateral 
CIs and were followed for 6 months. After 6 months of CI use, the 
patients showed an improvement in auditory thresholds with the use 
of the CI, with an average of 35 and 44 dB, respectively, and also had 
improved speech recognition [33].
The Glendonald Auditory Screening Procedure (GASP) rating scale 
shows that if the treatment is beneficial, the patient approaches an 
ideal result (close to 100%) in the first year of CI use. A delay of around 
24 months was necessary to achieve this goal (hit rate close to 100% 
in GASP) in the patients studied in this study, and showed a not so 
great improvement in the first year of CI use.
The performance in IT MAIS was better in patients compared to the 
performance by MUSS; however, it needs to be pointed out that IT 
MAIS has a greater focus on evaluation of the hearing, while the 
MUSS has a greater focus on oral language.
We believe that, despite these results in these rating scales, this should 
not be viewed with pessimism. There are publications of patients with 
NA achieving good results but more slowly with good recognition and 
categorization of words with increased CI usage time [8, 31, 32].
An important longitudinal prospective study that followed up to 140 
children with AN, in which 52 (37%) of them received CIs, highlighted 
that AN is a very heterogeneous clinical situation with an ample diversi-
fication of impairments. However, cochlear implantation could be a very 
good option for helping those children to achieve great hearing reha-
bilitation and speech development. Poor prognosis is related to central 
nervous diseases and multiple deficiencies. Here electrically-evoked in-
tracochlear compound action potential testing may be helpful to select 
patients with AN as potential good candidates to receive a CI [34].
It should be noted that the measure of pure tone thresholds, the rec-
ognition rate of speech, and the speech perception test are objective 
measures of great importance in indicating and monitoring patients 
with CI, particularly with oralized patients (post-lingual). But these 
tests have limitations, especially in not oralized patients.
This study showed improvement in all parameters of pure tone audi-
ometry and the speech preoperative recognition index (with the use 
of hearing aids) and postoperative (with CIs), with a statistical signif-
icance (p<0.05).
Such data in pre-lingual and not oralized patients, usually found in 
children and also in cases of AN, as well as all other cases in this arti-
cle, are secondary and only corroborate and support the benefits of 
language development of this therapeutic modality. Such benefits 
are valued mostly for subjective evaluations, often with the support 
and use of information from parents and/or caregivers and through 
scales that measure hearing and language improvements as used 
(GASP, IT MAIS, and MUSS).
Speech therapy before and after CI surgery is very important for the 
acquisition and development of speech. Our patients underwent this 
treatment in their hometown cities and there was no standardization 
of how this therapy occurred. With a standardized and regular speech 
therapy, it is possible that our results would be even more satisfying.
Cochlear Implantation is becoming a choice of treatment for patients 
with AN. This kind of hearing disorder with mild to moderate hearing 
loss is still a challenge regarding the treatments options, even to ex-
perts in this area.
This paper adds data to support CI as a treatment for AN patients 
and is the first Brazilian-Latin American review on this topic, and also 
has a greater importance for a better reflection and emplacement of 
clinical and management decisions. It is still necessary to study more 
patients and a larger study group to gain more significance data to 
support the conclusions of this study.
Auditory Neuropathy (AN) is a heterogeneous situation and is very 
difficult to study and analyze patients and outcomes. Besides, this 
is also a very rare condition. We did not find any difference between 
the groups (p>0.05) in all the analyses related to the age of implan-
tation, except that the Group 1 patients (CI before 4-years old) had 
more time of use with their CIs, which is normal because they were 
submitted to the surgery earlier than the others patients. Regarding 
residual hearing (low/moderate hearing loss vs. severe/profound 
hearing loss), we also did not find any difference between the groups 
(p>0.05) in all the analyses.
The statistical significance demonstrated through the GASP analysis and 
audiometric findings, and the correlation trend with the IT MAIS, are the 
strong indicators of the benefits of using a CI in patients with AN.
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The conclusion of this paper is that CI is an effective treatment for au-
ditory rehabilitation and language development in children with AN.
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